This trial is evaluating whether Etigilimab will improve 2 primary outcomes and 4 secondary outcomes in patients with Recurrent Fallopian Tube Clear Cell Adenocarcinoma. Measurement will happen over the course of From the date of dual therapy treatment initiation to the date of initial radiologic evidence of progressive disease or death, assessed up to 90 days after completion of treatment.
This trial requires 20 total participants across 1 different treatment group
This trial involves a single treatment. Etigilimab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The prognosis is poor in patients treated with surgery alone because of their advanced-stage disease and poor performance status. Patients with ovarian metastasis have better prognoses after cytoreductive surgery and intraperitoneal chemotherapy than patients with no evidence of ovarian metastasis. A prospective randomized trial would be necessary to determine whether patients with ovarian metastases benefit from cytoreductive surgery followed by intraperitoneal chemotherapy." - Anonymous Online Contributor
"Adenocarcinoma, clear cell is a rare type of tumor. Therefore, its causes are not well known. The most commonly reported cause is chronic renal failure. For example, pimozide usage is associated with increased risk of adenocarcinoma, clear cell in renal transplant recipients. We have also demonstrated that adenocarcinoma, clear cell has low expression of p16(INK4a) gene. Thus, we believe that this tumor is caused by other factors besides p53 mutation. Also, our results suggest that p53 mutation does not play a major role in the pathogenesis of this neoplasm." - Anonymous Online Contributor
"Etigilimab was well tolerated both In a recent study and in phase III trials. Serious adverse events were uncommon (3%). The most common side effects were infusion reactions (mostly injection site reactions), fatigue, nausea, vomiting, and diarrhoea. Results from a recent paper support the continued development of etigilimab in combination regimens for advanced solid tumours." - Anonymous Online Contributor
"Etigilimab is an anti-PDGFR antibody used in a number of advanced solid tumors in conjunction with other therapies. It has shown some efficacy in proof of concept studies in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC). While etigilimab has been granted orphan drug status in both those indications it has not yet progressed to phase III clinical trials. The first published clinical trial was terminated early due to safety concerns. A second clinical trial has recently been initiated in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). This trial is being conducted in collaboration with AstraZeneca." - Anonymous Online Contributor
"The majority of patients enrolled in this trial were not eligible for participation in conventional trials. In the absence of any evidence on the efficacy of enrollment criteria for metastatic sarcomas, prospective clinical trials evaluating eligibility criteria for metastatic sarcomas are warranted." - Anonymous Online Contributor
"Etiglitazar is a fully human monoclonal antibody directed against Interleukin-6 receptor alpha chain. It is a potent inhibitor of IL-6 signals and exerts its effects by blocking the interaction between IL-6 and IL-6Ralpha subunit. Etiglitazar inhibits the internalization of IL-6Ralpha by inhibiting the formation of endosomes, thus preventing IL-6 from binding to its specific receptor and thereby reducing the downstream signalling pathways." - Anonymous Online Contributor
"Treatment strategies for clear cell carcinoma are not well defined. In a recent study, we summarize the current knowledge on the management of clear cell carcinoma and propose an algorithm for treatment based on our experience and the literature." - Anonymous Online Contributor
"Adenocarcinoma, clear cell has 3 main subtypes based on the appearance of its cells under the microscope: clear cells, hobnail cells, and papillary cells. The clear cell form dominates among the three. In our study, the majority of patients had either clear cell or hobnail cell histology (97% vs 3%, respectively). In contrast, only 1 patient out of 5 had papillary cell histology. This may be due to the rarity of papillary cell tumors." - Anonymous Online Contributor
"This is an important question because adenocarcinomas of the pancreas can occur at any age, but most commonly occurs among middle-aged individuals. The incidence increases steadily in the fourth decade of life." - Anonymous Online Contributor
"Etigilimab administered once weekly was significantly more effective than a placebo in this phase II study. Efficacy of etigilimab was demonstrated in all subgroups except the elderly. Data from a recent study obtained suggest that further evaluations using etigilimab may be necessary." - Anonymous Online Contributor